BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37328102)

  • 1. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.
    Black LE; Longo JF; Anderson JC; Carroll SL
    Am J Pathol; 2023 Sep; 193(9):1298-1318. PubMed ID: 37328102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors.
    Friedrich RE; Nörnberg LKN; Hagel C
    Anticancer Res; 2022 May; 42(5):2327-2340. PubMed ID: 35489721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
    Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
    Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPAR1 and aberrantly expressed LPAR3 differentially promote the migration and proliferation of malignant peripheral nerve sheath tumor cells.
    Doutt SW; Longo JF; Carroll SL
    Glia; 2023 Mar; 71(3):742-757. PubMed ID: 36416236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors.
    Stonecypher MS; Byer SJ; Grizzle WE; Carroll SL
    Oncogene; 2005 Aug; 24(36):5589-605. PubMed ID: 15897877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.
    Eckert JM; Byer SJ; Clodfelder-Miller BJ; Carroll SL
    Glia; 2009 Nov; 57(14):1501-20. PubMed ID: 19306381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
    González-Muñoz T; Di Giannatale A; García-Silva S; Santos V; Sánchez-Redondo S; Savini C; Graña-Castro O; Blanco-Aparicio C; Fischer S; De Wever O; Creus-Bachiller E; Ortega-Bertran S; Pisapia DJ; Rodríguez-Peralto JL; Fernández-Rodríguez J; Pérez-Portabella CR; Alaggio R; Benassi MS; Pazzaglia L; Scotlandi K; Ratner N; Yohay K; Theuer CP; Peinado H
    Clin Cancer Res; 2023 Sep; 29(18):3744-3758. PubMed ID: 37432984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells.
    Kohli L; Kaza N; Lavalley NJ; Turner KL; Byer S; Carroll SL; Roth KA
    Neuro Oncol; 2012 Mar; 14(3):266-77. PubMed ID: 22259051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.
    Byer SJ; Eckert JM; Brossier NM; Clodfelder-Miller BJ; Turk AN; Carroll AJ; Kappes JC; Zinn KR; Prasain JK; Carroll SL
    Neuro Oncol; 2011 Jan; 13(1):28-41. PubMed ID: 21075781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
    Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
    Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
    Watson AL; Anderson LK; Greeley AD; Keng VW; Rahrmann EP; Halfond AL; Powell NM; Collins MH; Rizvi T; Moertel CL; Ratner N; Largaespada DA
    Oncotarget; 2014 Mar; 5(6):1502-14. PubMed ID: 24681606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
    Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
    Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades.
    Brosius SN; Turk AN; Byer SJ; Longo JF; Kappes JC; Roth KA; Carroll SL
    J Neuropathol Exp Neurol; 2014 Nov; 73(11):1078-90. PubMed ID: 25289889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.